FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy
Mesoblast has announced that the US Food and Drug Administration (FDA) has accepted a resubmitted biologics license application (BLA) for…
Mesoblast has announced that the US Food and Drug Administration (FDA) has accepted a resubmitted biologics license application (BLA) for…